Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05305287 · ClinicalTrials.gov registry record · Phase 4
Quantifying Hepatic Mitochondrial Fluxes in Humans
A Phase 4 study of Type 2 Diabetes and Non-alcoholic Fatty Liver Disease, sponsored by The University of Texas Health Science Center at San Antonio.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
- 2
- Study locations
NCT05305287: Recruiting Phase 4 study of Type 2 Diabetes and Non-alcoholic Fatty Liver Disease, sponsored by The University of Texas Health Science Center at San Antonio.
NCT05305287 is a Phase 4 study of Type 2 Diabetes and Non-alcoholic Fatty Liver Disease that is actively recruiting participants, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 60 participants, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05305287, a Phase 4 study of Type 2 Diabetes and Non-alcoholic Fatty Liver Disease, is actively recruiting participants, sponsored by The University of Texas Health Science Center at San Antonio.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
- 2
- Study locations
Study Summary
In this study the investigators will quantitate hepatic mitochondrial fluxes in T2D patients with NAFL and NASH before and after 16-weeks treatment with the insulin sensitizer pioglitazone
Primary Outcome
Quantitated using a combined stable isotope approach before and after treatment with pioglitazone
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Pioglitazone
Study Locations (2)
Texas
- Texas Diabetes Institute - University Health System - San Antonio
- University of Texas Health Science Center at San Antonio - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2022-11-01 |
| Est. Completion | 2027-03-31 |
| Phase | Phase 4 |
What NCT05305287 shows while recruiting
NCT05305287 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (98% lower).
The record links to 3 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05305287 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05305287 about?
NCT05305287 is a clinical study titled "Quantifying Hepatic Mitochondrial Fluxes in Humans". In this study the investigators will quantitate hepatic mitochondrial fluxes in T2D patients with NAFL and NASH before and after 16-weeks treatment with the insulin sensitizer pioglitazone
What is the current status of trial NCT05305287?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2022-11-01. Estimated completion is 2027-03-31.
What conditions does trial NCT05305287 study?
This clinical trial studies the following conditions: Type 2 Diabetes, Non-alcoholic Fatty Liver Disease, Mitochondrial Metabolism Disorders.
What interventions are being tested in trial NCT05305287?
The interventions under investigation include: Placebo (OTHER), Pioglitazone (DRUG).
Who is sponsoring clinical trial NCT05305287?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05305287 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05305287's enrollment target sits among peer trials
60 192nd of 327 higher than 124 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mechanism of SGLT2 Inhibition in the Kidney
RECRUITING · Phase 4
-
GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH
RECRUITING · Phase 4
-
DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study, a Randomized, Placebo-controlled, Cross-over Study With Ertugliflozin in People With Type 2 Diabetes
RECRUITING · Phase 4
-
Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes
RECRUITING · Phase 4
-
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
RECRUITING · Phase 4
-
DIALYSIS-TIR Study
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI